Learn more

INST MEDIZINTECHNOLOGIE MAGDEB

Overview
  • Total Patents
    20
About

INST MEDIZINTECHNOLOGIE MAGDEB has a total of 20 patent applications. Its first patent ever was published in 2000. It filed its patents most often in Germany, China and Canada. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and materials and metallurgy are CHELSEA THERAPEUTICS INC, COMPLEXA INC and ALLTRANZ INC.

Patent filings per year

Chart showing INST MEDIZINTECHNOLOGIE MAGDEBs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Ansorge Siegfried 16
#2 Lendeckel Uwe 15
#3 Reinhold Dirk 11
#4 Neubert Klaus 11
#5 Gollnick Harald 5
#6 Vetter Robert 5
#7 Tadje Janine 4
#8 Arndt Marco 4
#9 Buehling Frank 3
#10 Uwe Lendeckel 2

Latest patents

Publication Filing date Title
DE10330842A1 Use of the inhibitors of enzymes with activities of aminopeptidase N and / or dipeptidyl peptidase IV and pharmaceutical preparations thereof for the therapy and prevention of dermatological diseases with hyperproliferation and altered differentiation states of fibroblasts
DE10230381A1 Use of inhibitors of alanyl aminopeptidases and pharmaceutical compositions comprising them
WO02053170A2 Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type i according to the gell and coombs classification, and for the treatment and prevention of dermatological diseases associated with fo
DE10155093A1 Inhibiting DNA synthesis in T-lymphocytes, keratinocytes and TH2 cytokine production, comprises combined administration of dipeptidyl peptidase and alanyl-aminopeptidase inhibitors
DE10102392A1 Inhibiting DNA synthesis in T-lymphocytes, keratinocytes and TH2 cytokine production, comprises combined administration of dipeptidyl peptidase and alanyl-aminopeptidase inhibitors
DE10100052A1 Inhibiting DNA synthesis in T-lymphocytes, keratinocytes and TH2 cytokine production, comprises combined administration of dipeptidyl peptidase and alanyl-aminopeptidase inhibitors
DE10025464A1 Combined use of enzyme inhibitors for the therapy of autoimmune diseases, in transplants and tumor diseases, as well as combinations of pharmaceutical preparations comprising enzyme inhibitors